Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Phentermine
Drug ID BADD_D01756
Description Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine.[A174370] Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential).[A174367] Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers.[A174376, T403] Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to obtain the desired effect.[A174373]
Indications and Usage For the treatment and management of obesity.
Marketing Status Prescription; Discontinued
ATC Code A08AA01
DrugBank ID DB00191
KEGG ID D05458
MeSH ID D010645
PubChem ID 4771
TTD Drug ID D0U0RZ
NDC Product Code Not Available
Synonyms Phentermine | Duromine | Phentermine Hydrochloride | Hydrochloride, Phentermine | Adipex-P | Adipex P | AdipexP | Ionamine
Chemical Information
Molecular Formula C10H15N
CAS Registry Number 122-09-8
SMILES CC(C)(CC1=CC=CC=C1)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.0020.000494%
Insomnia19.02.01.002; 17.15.03.0020.001234%
Intestinal ischaemia24.04.08.001; 07.15.02.0010.001234%Not Available
Joint stiffness15.01.02.0030.001728%Not Available
Joint swelling15.01.02.0040.001974%Not Available
Menorrhagia21.01.03.0020.000494%
Muscular weakness15.05.06.001; 17.05.03.0050.001234%
Myalgia15.05.02.0010.002468%
Myocardial infarction24.04.04.009; 02.02.02.0070.000193%
Nausea07.01.07.0010.003208%
Neck pain15.03.04.0090.000987%
Nephrotic syndrome20.05.01.0020.001234%
Nervousness19.06.02.003--Not Available
Normochromic normocytic anaemia01.03.02.0050.000494%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.000494%
Pain08.01.08.0040.000987%
Pain in extremity15.03.04.0100.000740%
Palpitations02.01.02.0030.001728%
Panniculitis23.07.02.002; 10.01.03.0240.000494%Not Available
Parkinsonism17.01.05.0030.000494%Not Available
Peripheral coldness24.04.03.006; 08.01.09.0100.001974%Not Available
Pruritus23.03.12.001--
Pseudomembranous colitis11.02.02.002; 07.19.01.0030.001481%Not Available
Pulmonary embolism22.06.02.001; 24.01.06.0010.000494%Not Available
Pulmonary hypertension24.08.03.002; 22.06.01.001--
Pyrexia08.05.02.0030.000987%
Quadriplegia17.01.04.0130.000494%Not Available
Rash23.03.13.001--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.0010.000494%
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages